Cipla hits new high on DCGI nod to import Moderna vaccine; up 4% in 2 days

At this stage, there is no definitive agreement on commercial supplies, the company said in response to media queries on vaccine import

Shares of Cipla hit a record high of Rs 997.20 as they rose nearly 2 per cent on the BSE in intra-day trade on Wednesday after the Drugs Controller General of India (DCGI) permitted the firm to import Moderna's Covid Vaccine with emergency use authorisation in India. In the past two days, the scrip has gained 4 per cent.

At 09:34 am, the stock pared some gains and was trading 0.45 per cent higher at Rs 983.45 as compared to a 0.18 per cent gain in the S&P BSE Sensex. A combined 2.3 million shares had changed hands on the